Management of Vasospasm Post-Stenting After SAH

Immediate Medical Management

• The American Heart Association recommends ensuring nimodipine 60 mg every 4 hours is being administered for the full 21-day course, as this is the only medication proven to reduce neurological deficits from vasospasm (Class I, Level of Evidence A) 1, 2, 3
• The American College of Cardiology suggests that if nimodipine causes hypotension, attempt standard blood pressure support measures before reducing the dose 3

Hemodynamic Optimization

• The American Heart Association recommends inducing hypertension to elevate systolic blood pressure while maintaining euvolemia as the first-line treatment when delayed cerebral ischemia is diagnosed 2, 4
• The Neurocritical Care Society advises against prophylactic hypervolemia (triple-H therapy), as it is not recommended and may be harmful 1, 4

Endovascular Interventions

• The Society of NeuroInterventional Surgery recommends considering cerebral angioplasty if no improvement or deterioration occurs despite medical management 2, 4
• The American Heart Association suggests that balloon angioplasty is effective for proximal large vessels with thick muscular walls 2

Monitoring Strategy

• The Neurocritical Care Society recommends using transcranial Doppler monitoring with Lindegaard ratios (cerebral vessel velocity/extracranial ICA velocity) to diagnose vasospasm 2
• The American Heart Association advises maintaining a higher index of suspicion in poor-grade patients, as symptomatic vasospasm can occur without obvious symptoms in comatose patients 5

Adjunctive Management

• The American Heart Association recommends aggressively controlling fever toward normothermia using standard or advanced temperature modulation systems (Class IIa, Level of Evidence B) 6, 2
• The Neurocritical Care Society suggests using fludrocortisone acetate and hypertonic saline to prevent and correct hyponatremia (Class IIa, Level of Evidence B) 6, 2

Critical Pitfalls to Avoid

• The American College of Cardiology advises against discontinuing DAPT due to fear of hemorrhage, as the evidence shows protective effects against vasospasm without increased bleeding risk 1, 4
• The Neurocritical Care Society recommends avoiding prophylactic hypervolemia and instead maintaining euvolemia 1, 4

Therapies NOT Recommended

• The American Heart Association recommends against using statins, as they have no benefit in outcomes despite reduction in angiographic vasospasm 1
• The Neurocritical Care Society advises against using magnesium sulfate, as it has no benefit in cerebral infarction or mortality 1